P-glycoprotein: a clue to vitamin K antagonist stabilization. (January 2015)

• Record Type: Journal Article
• Authors: Gschwind, Liliane; Rollason, Victoria; Boehlen, Françoise; Rebsamen, Michela; Combescure, Christophe; Matthey, Alain; Bonnabry, Pascal; Dayer, Pierre; Desmeules, Jules Alexandre
• Is Part Of: Pharmacogenomics. Volume 16:Number 2(2015)
• Page Start: 129
• Page End: 136
• Publication Date: 2015-01
• Subjects: ABCB1 -- acenocoumarol -- drug transporter -- gene polymorphism -- pharmacogenetics -- P-glycoprotein -- vitamin K antagonists; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.14.164
• Languages: English
• ISSNs: 1462-2416

Abstract

Background: Acenocoumarol is a vitamin K antagonist used in some European countries. As warfarin, this drug is characterized by a narrow therapeutic index and a large interindividual variability.Aim: The objective of this study was to assess the involvement of ABCB1 polymorphisms on acenocoumarol treatment.Materials & methods : An observational cohort study was conducted to assess whether there is an association between the presence of the allelic variants of the ABCB1 gene coding for P-glycoprotein and acenocoumarol stabilization and daily doses during the first 35 days of treatment.Results : One hundred and fifteen patients met the inclusion criteria. The results of the clinical study showed that carriers of ABCB1 c.3435TT were more rapidly stabilized than wild-type patients (HR: 2.97, 95% CI: 1.23–7.18; p = 0.02). The same tendency was observed for the ABCB1 c.2677GT and 2677TT genotypes compared with ABCB1 c.2677GG. The ABCB1 c.2677TT genotype was also associated with a significant increase in doses of acenocoumarol (p = 0.03), the same tendency was observed with the ABCB1 c.3435TT genotype compared with the wild-type patients.Conclusion: These data suggest that ABCB1 polymorphisms could be involved in the response to acenocoumarol treatment. Original submitted 6 June 2014; Revision submitted 5 November 2014